l e t t e r s Because only a small fraction of asbestos-exposed individuals develop malignant mesothelioma 1 , and because mesothelioma clustering is observed in some families, we searched for genetic predisposing factors. We discovered germline mutations in the gene encoding BRCA1 associated protein-1 (BAP1) in two families with a high incidence of mesothelioma, and we observed somatic alterations affecting BAP1 in familial mesotheliomas, indicating biallelic inactivation. In addition to mesothelioma, some BAP1 mutation carriers developed uveal melanoma. We also found germline BAP1 mutations in 2 of 26 sporadic mesotheliomas; both individuals with mutant BAP1 were previously diagnosed with uveal melanoma. We also observed somatic truncating BAP1 mutations and aberrant BAP1 expression in sporadic mesotheliomas without germline mutations. These results identify a BAP1-related cancer syndrome that is characterized by mesothelioma and uveal melanoma. We hypothesize that other cancers may also be involved and that mesothelioma predominates upon asbestos exposure. These findings will help to identify individuals at high risk of mesothelioma who could be targeted for early intervention.
asbestos usage is increasing exponentially 8 . Erionite shares physical characteristics with asbestos and also causes mesothelioma 1 . With increased urban development, exposure also occurs from disturbance of asbestos-and erionite-containing soil 9, 10 .
Some individuals develop mesothelioma following exposure to small amounts of asbestos, whereas others exposed to heavy amounts do not 1 . We have reported mesothelioma clustering in some US and Turkish families in which up to 50% of members developed mesothelioma 11 . This incidence far exceeds that observed in cohorts exposed to high levels of asbestos (4.6%).
Over the past 14 years, we prospectively studied families with high incidence of mesothelioma to identify putative mesotheliomasusceptibility genes. We focused on two US mesothelioma families, one in Wisconsin (W family) and one in Louisiana (L family), in which members were neither exposed to erionite nor had occupational exposure to asbestos, thus removing the confounding factor of heavy exposure to carcinogens known to cause a high incidence of mesothelioma. Family members developed various malignancies, although mesothelioma predominated (Fig. 1a,b and Supplementary Table 1 ).
Array-comparative genomic hybridization (CGH) analysis of two tumors (one per family) uncovered alterations encompassing or adjacent to the BAP1 locus at 3p21.1. In one tumor, W-III-06T (T indicates 'tumor'), a transition in copy number occurred at or near the BAP1 promoter, whereas in the second, L-III-18T, a focal deletion encompassing BAP1 resided within a larger deletion ( Fig. 2a) . We also performed linkage studies on germline DNA from each family. In a joint parametric analysis of the two families, the largest linkage peak, reaching a maximum lod score of 2.1, occurred at 3p21-22 ( Supplementary Fig. 1) . Although the region implicated in linkage analyses, which assumed that only those with mesothelioma were affected, was large and included many genes, a much smaller region was implicated by the array-CGH analysis, including a genomic imbalance l e t t e r s beside the BAP1 locus and an ~218-kb homozygous deletion that encompassed BAP1. Moreover, this smaller region was congruent with a smaller linkage region obtained in the W family assuming that all those with cancer, including kidney, ovary and early onset breast carcinomas, carried the same risk allele.
These findings, coupled with the fact that 3p21.1 is a site of recurrent chromosomal loss in sporadic mesotheliomas [12] [13] [14] , prompted our pursuit of this gene. BAP1 is a nuclear protein that enhances BRCA1mediated inhibition of breast cancer cell proliferation, acting as a tumor suppressor in the BRCA1 growth control pathway and regulating proliferation by de-ubiquitinating host cell factor-1 (HCF-1) 15, 16 .
We sequenced BAP1 in germline DNA from family W and found that six affected members (four with mesothelioma, two with breast or renal cancer) had identical mutations, whereas unaffected family members did not ( Fig. 1a) . Mutation status was consistent with the results of the linkage analysis, the latter additionally establishing that case W-III-10 (ovarian cancer) was a BAP1 mutation carrier.
The germline mutation in family W occurred at the intron 6-exon 7 boundary, with affected individuals having an A→G substitution at the −2 nucleotide consensus splice acceptor site ( Supplementary Fig. 2a ). Such alterations lead to exon skipping and disease-causing protein changes 17, 18 . Transfection of mammalian cells with a genomic construct containing exons 6-8 and with the intron 6 splice-site mutation resulted in an aberrant splice product lacking exon 7 ( Supplementary  Fig. 2b ) and a frameshift that is predicted to lead to a premature stop codon ( Fig. 2b) and nonsense-mediated decay.
Besides the somatic genetic alteration detected by array CGH in sample W-III-06T, only mutant BAP1 could be detected in tumor W-III-08T, consistent with loss of wild-type BAP1 on the other chromosome. Additionally, W-III-04T had both the splice-site mutation and a 25-bp exon 4 deletion, resulting in a frameshift and premature termination of BAP1 (p.Ile72fsX7) ( Supplementary Fig. 2c ). Matched germline DNA lacked the deletion, indicating a somatic origin. Cloning of genomic PCR products encompassing exons 4-7 from tumor DNA Figure 1 Pedigrees of two US families with high incidence of mesothelioma. (a,b) Pedigrees showing family members with a germline mutation in BAP1, as confirmed by both sequencing and linkage analyses (orange) or by linkage analysis alone (yellow; that is, no DNA was available for sequencing); individuals without the mutation (green) and individuals for whom DNA was unavailable (blue) are also shown. The presence or absence of germline BAP1 mutation is also indicated with + or − symbols, respectively. (a) Pedigree of family W showing the presence or absence of a germline mutation at the BAP1 consensus splice acceptor site. (b) Pedigree of family L showing the presence or absence of a germline nonsense mutation. The development of other tumor types (supplementary table 1) in these families may also be related to BAP1 germline mutations. In family W, the presence of a case of breast cancer before age 45 and a case of ovarian cancer suggests that the BAP1 mutation may be associated with a hereditary form of breast and ovarian cancer. In family L, the skin cancers shown were squamous-cell carcinomas. Available mesothelioma tumor specimens with a germline splice-site mutation and either a somatic 25-bp deletion (W-III-04T), genomic alteration (W-III-06T) or loss of the wild-type BAP1 allele (W-III-08T) are indicated in supplementary table 1, as is the homozygous deletion of BAP1 seen in mesothelioma specimen L-III-18T. ) and an amplicon adjacent to BAP1 locus (tumor W-III-06T). The BAP1 gene resides at chr3:52,435,027-52,444,009, and the Agilent Human 244K chip contains two probes within the BAP1 locus: A_16_P00704764 (chr3:52,438,014-52,438,066) and A_14_P128339 (chr3:52,443,209-52,443,268). In W-III-06T, the two BAP1 probes had log 2 ratios indicative of normal diploid DNA copy numbers, whereas the log 2 ratios of two probes immediately centromeric of BAP1 showed a transition to a higher copy number, indicating the start of an amplified region at or near the BAP1 promoter (zoomed-in image and further details shown in supplementary Fig. 6 ).
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In L-III-18T, the focal homozygous deletion encompassed the entire BAP1 locus and was ~218 kb. (b) Schematic diagram of predicted truncations of BAP1 resulting from the germline mutations observed in two families (W and L) with high incidence of mesothelioma, as well as in two sporadic cases of mesothelioma in individuals who had previously developed uveal melanomas (SP-002; SP-008).
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In family L, germline DNA from three individuals with mesothelioma (one recently treated for uveal melanoma) and two with skin carcinomas had a C/G-to-T/A transition in exon 16, creating a stop codon (p.Gln684X) ( Fig. 2b and Supplementary Fig. 2d ). There was complete concordance between BAP1 mutation status and linkage analysis. Linkage analyses also showed that individual L-II-03 (who had pancreatic cancer) was a mutation carrier.
Exome sequencing of germline DNA from two affected members of each family using the Illumina HiSequation (2000) system verified the splice-site and nonsense mutations in family W and family L, respectively (data not shown). Immunohistochemistry on mesotheliomas from families L and W showed lack of BAP1 nuclear expression ( Fig. 3) .
Although occupational histories did not suggest any obvious exposure in these families, we detected chrysotile asbestos in five of the five homes in which all affected family-L members had lived (consistent with the high percentage of asbestos-containing houses in the town where the family resided); we also found traces of tremolite and chrysotile asbestos in the home in which all affected members of family W were raised ( Supplementary Figs. 3 and 4) . About 30 million US homes contain asbestos 4 ; both families lived in such homes. Living in an asbestos-containing home is associated with modest levels of exposure, as observed in individuals who have not been occupationally exposed, who represent a growing fraction of those with mesothelioma.
Having linked BAP1 mutations to familial mesothelioma, we next sequenced BAP1 (17 exons, introns and promoter) in 26 germline DNAs from individuals with sporadic mesothelioma. All had reported asbestos exposure to the treating physician, although these claims were not verified by lung content or mineralogical analyses. Two of the 26 individuals had germline BAP1 deletions: c.1832delC in exon 13 (p.Leu573fsX3) and c.2008-2011delTCAC in exon 14 (p.Ser628fsX8) ( Supplementary Table 1 ). Both mutations result in a frameshift leading to a stop codon upstream of the region encoding the BAP1 nuclear localization signal (Fig. 2b) . When we investigated whether anything was unique about these two cases, we found that each individual had been treated for uveal melanoma before being diagnosed with mesothelioma (6 years and 1 year earlier, respectively). Of the remaining 24 individuals with sporadic mesotheliomas, none had uveal melanoma. Tumor DNA was available from 18 of the 26 sporadic mesothelioma cases: DNA sequencing identified truncating BAP1 mutations in 4 of 18 (22%) tumors (Fig. 4a) ; BAP1 alterations in these tumors were supported by immunoblot analyses (Fig. 4b) . Also, 7 of 12 mesothelioma cell lines tested showed loss of BAP1 expression ( Supplementary  Fig. 5a ). Re-expression of BAP1 in BAP1-deficient mesothelioma cells markedly decreased colony-forming ability (Supplementary Fig. 5b) , consistent with the known role of BAP1 in regulating tumor cell proliferation and viability 15, 16 .
Frequent somatic mutations of BAP1 were reported in metastasizing uveal melanomas, with one affected individual having a germline mutation 19 . An association between uveal melanoma, breast cancer and ovarian cancer has been proposed 20 . Neither study uncovered any mesothelioma, possibly because the individuals studied had not been exposed to asbestos. A paper published while our manuscript was under review reported somatic BAP1 mutations in 23% of sporadic mesotheliomas 21 , which concurs with our findings in sporadic tumors. In addition, and most notably, we show the presence of germline BAP1 mutations in members of US families that experience an extremely high incidence of 5) and from a sporadic tumor lacking a BAP1 mutation (lane 1). Sporadic mesotheliomas with somatic BAP1 mutations show decreased expression of BAP1 compared to that seen in tumors without BAP1 mutation. Note that, in mesotheliomas, whole-tumor cell lysates inevitably contain some normal stromal cells that may be responsible for the faint BAP1 signal detected. Also note the presence of an additional, faster-migrating BAP1 band in the sample shown in lane 4 (SP-013), suggesting the presence of a truncated form of BAP1. The BAP1 protein products predicted in tumors SP-001 and SP-015 were not observed, suggesting nonsense-mediated mRNA decay. The mutation in tumor SP-018 results in a predicted protein product only 15 residues smaller, which presumably precludes detection of a small change in molecular weight compared to wild-type BAP1. GAPDH was used as a loading control. UHC domain BRCA1 interaction domain l e t t e r s mesothelioma, despite only modest exposure to asbestos. Furthermore, we show that BAP1 mutations are associated with a new hereditary cancer syndrome that predisposes to mesothelioma, uveal melanoma and potentially other cancers. The incidence of uveal melanoma is 5-7/100,000 in the United Stated 22 , similar to the incidence of mesothelioma 1 . Therefore, it is unlikely that the occurrence of both malignancies in the same individual would arise by chance; for example, if we assume the two diseases are independent and the joint probability (estimated at 36 per trillion per year) follows a binomial distribution, then the likelihood of three (or more) cases with both malignancies appearing in the United States (population ~310 million) per year is 2.3 × 10 −7 .
The average age of diagnosis of uveal melanoma is 56, with 5-year survival rates of 70-99% depending on tumor size and histology 22 . Mesothelioma is diagnosed later in life, and a 5-year survival is extremely rare and limited to cases diagnosed during the very early stages of tumor growth, when patients can undergo cytoreductive surgery 1,2 . Altogether, we observed BAP1 mutations in four individuals with uveal melanoma, three of whom subsequently developed mesothelioma; the fourth (L-II-18) died of metastatic uveal melanoma to the liver (Fig. 1b) , and DNA was not available. Thus, our findings suggest that individuals with uveal melanoma who carry germline BAP1 mutations are at high risk of developing mesothelioma and should be closely monitored.
Our results provide the first demonstration that germline alterations influence the risk of mesothelioma, a cancer linked to mineral fiber carcinogenesis. As observed for BRCA1 and BRCA2, which account for only some hereditary breast carcinomas, it seems likely that genes in addition to BAP1 will be found associated with elevated risk of mesothelioma. Indeed, among the 26 individuals with sporadic mesothelioma we studied, and excluding malignancies common in the sixth to eighth decades of life such as skin and prostate carcinomas, nine had been diagnosed with one or more additional tumors (Supplementary Table 1 ). Seven of 26 were females, and two of seven also had uterine leiomyosarcoma, a malignancy with an incidence of ~10/10 6 per year in the United States; one also had uveal melanoma, an unlikely coincidence.
In summary, we demonstrate the existence of a BAP1-related cancer syndrome characterized by mesothelioma, uveal melanoma and possibly other cancer types. We hypothesize that when individuals with BAP1 mutations are exposed to asbestos, mesothelioma predominates. Alternatively, BAP1 mutation alone may be sufficient to cause mesothelioma.
MeThods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. BAP1 protein mutation nomenclature numbering is based on accession NP_004647.1.
oNLINe MeThods
Subjects. Individuals with mesothelioma, uveal melanoma and other cancer types were diagnosed at the treating hospitals. Mesothelioma diagnoses were independently reviewed by M. Carbone, a board-certified pathologist and expert in mesothelioma diagnosis. Informed consent was obtained from all participants (affected and unaffected family members) according to the institutional guidelines of the University of Hawaii. DNA was extracted from peripheral blood using standard methods. There was no relationship between the two sporadic mesothelioma cases with BAP1 mutations and the L and W families. The uveal melanomas were treated by laser or radiation therapy; therefore, no biopsies were available.
Genetic linkage studies. Germline DNA samples from all available family members were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. Allele calls were performed by plate using the BIRDSEED version 2 algorithm, resulting in 906,600 SNPs for quality-control analyses 23 . We used PLINK 24 to remove SNPs with a minor allele frequency (MAF) below 5% in HapMap 25 CEU samples (ethnicity matched using EIGENSTRAT 26 ; data not shown), SNPs monomorphic in our data and SNPs with less than perfect call rates. We also used PLINK to verify relationships in the pedigrees by generating estimates for the proportion of SNPs inherited identically by descent among family members. For this analysis, HapMap CEUs were included in the sample to generate reference allele frequencies. Genetically corrected pedigrees were created using CRANEFOOT 27 . Parametric linkage analyses used an ~0.2-cM SNP map (high-MAF SNPs were selected to improve information content), assumed a rare dominant model and were conducted using ALLEGRO 28 . We used linkage analyses to test for haplotypic sharing of the region identified in the studies of affected mesothelioma cases as harboring the mutation in family members with non-mesothelioma cancers. These analyses demonstrated the co-segregation of the mutation with alternative cancers in the families, which was further confirmed through sequencing. Analyses to confirm the presence or absence of the mutation in additional cancer cases was inferred based on an ~0.05-cM SNP haplotype map enriched with 609 additional SNPs within 2 Mb of BAP1 to help resolve the boundaries of recombination events.
Cloning and sequence analysis. Cloning of genomic PCR products and DNA sequencing (independently performed at Fox Chase Cancer Center and University of Hawaii Cancer Center to verify reproducibility) were carried out using standard procedures. Nine PCR products encompassing the BAP1 coding exons, adjacent intron sequences and 5′ and 3′ untranslated regions were PCR amplified for sequencing. PCR primers used to amplify the BAP1 gene for sequencing are shown in Supplementary Table 2 . Advantage2 DNA polymerase (Clontech) was used with each pair of primers under the following conditions: denaturation at 95 °C for 2 min; then five cycles of 95 °C for 1 min and 68 °C for 1 min; then 35 cycles of 95 °C for 30 s, 63 °C for 30 s and 68 °C for 30 s; concluding with 68 °C for 5 min. PCR products were gel-purified and Sanger sequenced. To investigate the splice acceptor site mutation seen in family W, we used a PCR-based strategy to clone genomic BAP1 sequences encompassing exons 6-8 and intervening introns, including the intron 6 splice mutation. Primers incorporated an XhoI restriction site at the 5′ end and an EcoRI restriction site at the 3′end of the PCR product. Gel-purified PCR products were cloned into pcDNA 3.1(−) plasmid (Invitrogen) using the two restriction sites. Individual clones were sequence verified. Numbering of locations of mutations is based on the February 2009 human reference sequence (GRCh37/hg19).
Exome sequencing. DNA libraries were prepared from 2 µg genomic DNA using a modification of Illumina's Genomic PE Sample Prep Kit protocol (Illumina) in which all DNA purification steps were performed with AMPure SPRI bead purification (Beckman Coulter Genomics). Coding sequences were captured using the Agilent SureSelect Target Enrichment System with the Human All Exon Kit targeting 50 Mb of sequence. The captured DNA libraries were PCR amplified using the manufacturer's paired-end PCR primers and sequenced in one lane of an Illumina Genome Analyzer II× generating two 120-bp reads. For data processing and analysis, sequence reads were mapped to the reference genome (hg18) using the SamTools package and BWA. Duplicated reads were removed with Picard. Recalibration of base quality and indel realignment was performed with the GATK package. Single-nucleotide variants and indel variants were identified using the Unified Genotyper caller of the GATK package consisting of 44 samples, including samples from other projects. Mutations were annotated with SeattleSeq Annotation (http://gvs. gs.washington.edu/SeattleSeqAnnotation/). Splicing assay. This assay was performed using a minigene expression construct. Genomic DNA encompassing exons 6-8 of wild-type or splice-sitemutant BAP1 was cloned into pcDNA 3.1(−). Plasmids were transfected into 293T cells.
DNA copy number analysis. Oligonucleotide tiling array-CGH analysis was performed using 244K Human Genome CGH microarrays (G4411B) from Agilent Technologies. DNA (2-3 µg) from formalin-fixed, paraffinembedded mesothelioma specimens was labeled using Agilent's Genomic DNA ULS Labeling Kit. Hybridization and DNA copy number analysis were as described 29 .
Protein blot analysis. Immunoblot analysis was performed as described 29, 30 . BAP1 (C-4) and GAPDH antibodies were from Santa Cruz Biotechnology. Tumor cell lines used for immunoblotting were established from surgically resected primary human mesothelioma specimens as described 31 .
Immunohistochemistry. Immunohistochemical analysis was as described 30 . Both BAP1 C-4 (1:100) antibody from Santa Cruz and rabbit polyclonal antibody N-term (1:100) from Abgent were used, with similar results. Clonogenicity assay. This assay was performed by seeding BAP1-deficient mesothelioma cell lines (2 × 10 5 cells per well) in six-well plates and incubating at 37 °C overnight. Cells were transfected with 2 µg of wild-type BAP1 plasmid (OriGene) or control vector using Lipofectamine 2000 (Invitrogen). At 48 h after transfection, cells were selected in medium containing 400 µg ml −1 G418 (Invitrogen). At 2 weeks after selection, colonies were stained with Diff-Quik stain (Dade Behring).
Mineralogical studies. We collected and tested samples from the ceiling, roof, tiles, driveways and other surfaces of each house in which the L and W families lived 20 years ago or more, as mesothelioma latency is 30-50 years from initial exposure 1 , and we also tested nearby soil. Samples were analyzed as described 11 . Scanning electron microscopy, X-ray diffraction, transmission electron microscopy, energy dispersive spectroscopy (or X-ray microanalysis) and electron diffraction (or selected area electron diffraction) were performed on all samples collected to detect and correctly identify fibers.
